New targeted pill with chemotherapy for EGFR-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new targeted pill called TY-9591 combined with chemotherapy as a first treatment for advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the current standard of care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old.
- You must have a type of lung cancer called non-squamous non-small cell lung cancer that is advanced (stage IIIB, IIIC, IVA, or IVB) and cannot be removed with surgery.
- Your tumor must have a change called an EGFR mutation (specifically exon 19 deletion or L858R).
- You cannot have had any previous treatment for advanced lung cancer. (Prior treatment for early-stage cancer is okay if the cancer came back more than a year after treatment.)
- You must have at least one tumor that can be measured on a scan and has not been treated with radiation.
- You must be in good general health, with a performance status of 0 or 1 (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This study tests a new targeted pill (YK-029A) versus standard chemotherapy as the first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the targeted pill works better and has fewer side effects.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.